INVICRO A KONICA MINOLTA COMPANY

What this means for you

This application is over — abandoned 09 Jan 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

97016583

Mark type

Design + words

Filed

08 Sept 2021

Abandoned

09 Jan 2023

Attorney of record

Carrie L. Kiedrowski

Goods and services

• Class 009 — Scientific and electric apparatus: Downloadable computer software for processing, visualizing, storing and analyzing pre-clinical and clinical radiology and pathology image data in the fields of drug development and disease research; downloadable computer software for image data management purposes, namely, pre-clinical and clinical image database management and research subject records management; downloadable computer software for processing multi-modal imaging data; downloadable computer software for the processing, storage and analysis of multi-modal imaging data for quantitation and evaluation of biomarkers and drug candidates; downloadable software for the assessment of tumors for research through use of biomarkers
• Class 041 — Education and entertainment services: Educational services, namely, developing, arranging and conducting educational programs, panel discussions and webinars in the fields of pharmaceuticals, biotechnology, pre-clinical and clinical trials, and medical research; educational services, namely, providing non-downloadable publications, and literature in the fields of pharmaceuticals, biotechnology, pre-clinical and clinical trials, and medical research
• Class 042 — Scientific and technological services: Medical and scientific research, namely, conducting clinical and pre-clinical trial services for others; pharmaceutical research and development services; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms; imaging services and pathology in support of pharmaceutical research and development; drug discovery services; conducting early evaluations in the field of new drugs; scientific investigations for medical research purposes; medical and scientific research laboratory services; medical and scientific research, namely, providing analysis of imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; research and development in the fields of medical imaging, pharmaceuticals and biotechnology; design, development, maintenance and updating of computer software for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; electronic storage of medical images; processing and analysis of medical images; pathology services in support of drug development; hosting of a medical imaging analysis and visualization platform through a global computer network; hosting of a database of medical images; software as a service (SAAS) featuring computer software platforms for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; conducting clinical trials for others at all stages and in various indications, particularly in oncology, neurology and systemic diseases; imaging contract research organization services and technology solutions, namely, imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blinded independent central review of radiology images in the medical research and clinical trial setting; scientific research services, namely, integration of imaging results with clinical outcome data, with application of machine learning and artificial intelligence applications; development and evaluation of imaging biomarkers for clinical trial purposes; software consulting services in the field of drug discovery; cloud computing featuring software for use in pharmaceutical drug research in the field of drug discovery; radiochemistry services; research, development and testing services relating to radiopharmaceuticals; radiolabeling scientific research, namely, labeling of both small molecules and biologics; providing non-downloadable web-based computer software for database management in the fields of medical imaging, pharmaceutical and biotechnology research
• Class 044 — Medical, beauty and agricultural services: Medical imaging services; medical imaging and radiology services related to drug development; research services in the fields of magnetic resonance and molecular imaging; medical research services, in particular services relating to the development of radiotherapeutics and drug candidates for neurodegenerative diseases and precision oncology; image analysis and radiology, namely, analysis of images from all radiological modalities, such as but not limited to CT, MRI and PET scans to provide quantitative evaluation of drug candidates medical radiology, namely, molecular imaging, imaging utilizing radiopharmaceuticals; radiomics, namely, medical radiology services; medical imaging services, namely, medical imaging and extraction of imaging biomarkers; pathology services, namely, testing for research purposes in the fields of pharmaceuticals and biotechnology; pathology services for preclinical biomarker discovery research and clinical trials

Owner

• Invicro, LLC, Needham, MA, US

Prosecution history

• 19 Jan 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
• 19 Jan 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
• 19 Jan 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 06 Dec 2022 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
• 06 Dec 2022 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 06 Dec 2022 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 06 Dec 2022 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 06 Dec 2022 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
• 07 Jul 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 07 Jul 2022 — NON-FINAL ACTION E-MAILED
• 07 Jul 2022 — NON-FINAL ACTION WRITTEN
• 13 Jun 2022 — ASSIGNED TO EXAMINER
• 19 Oct 2021 — NOTICE OF DESIGN SEARCH CODE E-MAILED
• 18 Oct 2021 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 11 Sept 2021 — NEW APPLICATION ENTERED